TY - JOUR
T1 - Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations
T2 - A Work Group Report of the AAAAI Committee on the Underserved
AU - Davis, Carla M.
AU - Apter, Andrea J.
AU - Casillas, Adrian
AU - Foggs, Michael B.
AU - Louisias, Margee
AU - Morris, Elsie C.
AU - Nanda, Anil
AU - Nelson, Michael R.
AU - Ogbogu, Princess U.
AU - Walker-McGill, Cheryl Lynn
AU - Wang, Julie
AU - Perry, Tamara T.
N1 - Funding Information:
We thank Drs Melody Carter, Russell Tomar, John Carlson, Maboobeh Mahdavinia, and Deidre Crocker for careful review of this manuscript and Megan Brown from the American Academy of Allergy, Asthma & Immunology for administrative assistance. Disclosure of potential conflict of interest: C. M. Davis receives research grant support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (UM2 AI130836, U01 AI126614, R01 AI135197, U54 AI117804), DBV Technologies, Aimmune Therapeutics, Nutricia North America, Regeneron Pharmaceuticals, and the Scurlock Foundation and is a consultant for Moonlight Therapeutics. A. J. Apter receives research grant support from National Institutes of Health/National Heart, Lung, and Blood Institute and Patient-Centered Outcomes Research Institute; consults for UpToDate; and is an associate editor for the Journal of Allergy and Clinical Immunology. M. B. Foggs serves on the advisory boards for Boehringer Ingelheim and Sanofi/Regeneron and is a consultant for AstraZeneca. M. R. Nelson is president of the American Board of Allergy & Immunology and a Board member and Oversight Task Force member of the American Board of Medical Specialties. P. U. Ogbogu serves on the advisory boards for AstraZeneca and GlaxoSmithKline. C. L. Walker-McGill is chair of the Board of the Federation of State Medical Boards. J. Wang receives research grant support from the National Institutes of Health/National Institute of Allergy and Infectious Disease, Aimmune, DBV Technologies, and Regeneron; is a consultant for Insignis Therapeutics and Genentech; served on the advisory board for DBV Technologies; is a member of the data monitoring committee for ALK Abello; and is an UpToDate author. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
Disclosure of potential conflict of interest: C. M. Davis receives research grant support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (UM2 AI130836, U01 AI126614, R01 AI135197, U54 AI117804), DBV Technologies, Aimmune Therapeutics, Nutricia North America, Regeneron Pharmaceuticals, and the Scurlock Foundation and is a consultant for Moonlight Therapeutics. A. J. Apter receives research grant support from National Institutes of Health/National Heart, Lung, and Blood Institute and Patient-Centered Outcomes Research Institute; consults for UpToDate; and is an associate editor for the Journal of Allergy and Clinical Immunology. M. B. Foggs serves on the advisory boards for Boehringer Ingelheim and Sanofi/Regeneron and is a consultant for AstraZeneca. M. R. Nelson is president of the American Board of Allergy & Immunology and a Board member and Oversight Task Force member of the American Board of Medical Specialties. P. U. Ogbogu serves on the advisory boards for AstraZeneca and GlaxoSmithKline. C. L. Walker-McGill is chair of the Board of the Federation of State Medical Boards. J. Wang receives research grant support from the National Institutes of Health/National Institute of Allergy and Infectious Disease, Aimmune, DBV Technologies, and Regeneron; is a consultant for Insignis Therapeutics and Genentech; served on the advisory board for DBV Technologies; is a member of the data monitoring committee for ALK Abello; and is an UpToDate author. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2021
PY - 2021/5
Y1 - 2021/5
N2 - Health disparities are health differences linked with economic, social, and environmental disadvantage. They adversely affect groups that have systematically experienced greater social or economic obstacles to health. Renewed efforts are needed to reduced health disparities in the United States, highlighted by the disparate impact on racial minorities during the coronavirus pandemic. Institutional or systemic patterns of racism are promoted and legitimated through accepted societal standards, and organizational processes within the field of medicine, and contribute to health disparities. Herein, we review current evidence regarding health disparities in allergic rhinitis, asthma, atopic dermatitis, food allergy, drug allergy, and primary immune deficiency disease in racial and ethnic underserved populations. Best practices to address these disparities involve addressing social determinants of health and adopting policies to improve access to specialty care and treatment for the underserved through telemedicine and community partnerships, cross-cultural provider training to reduce implicit bias, inclusion of underserved patients in research, implementation of culturally competent patient education, and recruitment and training of health care providers from underserved communities. Addressing health disparities requires a multilevel approach involving patients, health providers, local agencies, professional societies, and national governmental agencies.
AB - Health disparities are health differences linked with economic, social, and environmental disadvantage. They adversely affect groups that have systematically experienced greater social or economic obstacles to health. Renewed efforts are needed to reduced health disparities in the United States, highlighted by the disparate impact on racial minorities during the coronavirus pandemic. Institutional or systemic patterns of racism are promoted and legitimated through accepted societal standards, and organizational processes within the field of medicine, and contribute to health disparities. Herein, we review current evidence regarding health disparities in allergic rhinitis, asthma, atopic dermatitis, food allergy, drug allergy, and primary immune deficiency disease in racial and ethnic underserved populations. Best practices to address these disparities involve addressing social determinants of health and adopting policies to improve access to specialty care and treatment for the underserved through telemedicine and community partnerships, cross-cultural provider training to reduce implicit bias, inclusion of underserved patients in research, implementation of culturally competent patient education, and recruitment and training of health care providers from underserved communities. Addressing health disparities requires a multilevel approach involving patients, health providers, local agencies, professional societies, and national governmental agencies.
KW - Health disparities
KW - allergic rhinitis
KW - asthma
KW - atopic dermatitis
KW - coronavirus disease 2019
KW - drug allergy
KW - food allergy
KW - primary immunodeficiency
UR - http://www.scopus.com/inward/record.url?scp=85105829732&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2021.02.034
DO - 10.1016/j.jaci.2021.02.034
M3 - Article
C2 - 33713767
AN - SCOPUS:85105829732
SN - 0091-6749
VL - 147
SP - 1579
EP - 1593
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 5
ER -